Skip to main content

Table 4 Antibiotic susceptibility of Pseudomonas aeruginosa bloodstream infection isolates, and the definitive antibiotic therapy used during the study period

From: Pseudomonas aeruginosa bloodstream infection at a tertiary referral hospital for children

Antibiotic

Susceptibility of PA isolates to anti-pseudomonal antibiotics

Antibiotics used as definitive antibiotic therapy

HAI N = 60

n/N (%)

IPOA

N = 31

n/N (%)

Total

N = 91

n/N (%)

HAI

N = 60 n/N (%)

IPOA

N = 31

n/N (%)

Total

N = 91

n/N (%)

Gentamicin

43 (71.7)

28 (90.3)

71 (78.0)

5 (8.3)

2 (6.5)

7 (7.7)

Amikacin

50 (83.3)

28 (90.3)

78 (85.7)

10 (16.7)

6 (19.4)

16 (17.6)

Ciprofloxacin

42 (70.0)

28 (90.3)

70 (76.9)

12 (20.0)

7 (22.6)

19 (20.9)

Piperacillin-tazobactam

35 (58.3)

19 (61.3)

54 (59.3)

12 (20.0)

9 (29.0)

21 (23.1)

Ceftazidime

50 (83.3)

29 (93.5)

79 (86.8)

8 (13.3)

8 (25.8)

16 (17.6)

Cefepime

47 (78.3

26 (83.9)

73 (80.2)

11 (18.3)

2 (6.5)

13 (14.3)

Meropenem

44 (73.3)

28 (90.3)

72 (79.1)

27 (45.0)

10 (32.3)

37 (40.7)

Imipenem

Colistin

43 (71.7)

-

27 (87.1)

-

70 (76.9)

-

2 (3.3)

9 (15)

0 (0)

-

2 (2.2)

9 (9.9)

  1. PA Pseudomonas aeruginosa, HAI Healthcare-associated infection, IPOA Infection present on admission.